New COVID Variant PJ.2.1 Spreads From Canada to USA and Europe: Coronavirus Raises Fresh Concerns Over SARS CoV 2 and Spike Protein Mutations

International News: Coronavirus Alert as New COVID 19 Variant PJ.2.1 Spreads From Canada to USA, Europe and Other Countries; Scientists Examine SARS CoV 2 Spike Protein Mutations and Potential Health Risks

The coronavirus has once again attracted international attention following the emergence of a new COVID-19 variant, PJ.2.1. First identified in Canada in May 2026, the new variant has subsequently been detected in several countries, including the United States, France, Spain, Australia, New Zealand and Singapore. Its growing presence has prompted scientists to investigate its genetic characteristics, transmission potential and ability to interact with human cells.

The development has raised fresh questions about the continued evolution of SARS CoV 2, the virus responsible for COVID 19. Researchers are particularly examining mutations in its Spike Protein, which plays a crucial role in allowing the virus to enter human cells. However, experts have not yet established that the new variant causes more severe illness than previously circulating strains.

What Is the New COVID-19 Variant PJ.2.1?

PJ.2.1 is a newly identified lineage of SARS-CoV-2 that was first detected in Ontario, Canada, on May 2, 2026. According to preliminary research published in October 2026, the variant originated from MC.10.1.7, a descendant of the JN.1 lineage.

Scientists have described PJ.2.1 as a saltation variant. This term refers to a virus that emerges with a relatively large number of genetic changes rather than developing through several smaller mutations over time.

Following its initial identification in Canada, additional cases were reported in provinces such as Alberta, British Columbia and New Brunswick. The variant was subsequently detected in other parts of the world, attracting attention from international health researchers.

New COVID Variant Reaches USA and European Countries

The spread of PJ.2.1 is no longer limited to Canada. The United States reported its first detection in New York City on June 30, 2026. Subsequent detections were reported in several states, including California, Arizona, New Jersey, Florida and Virginia.

In Europe, the variant has been identified in countries such as France and Spain. Researchers have also reported detections in Israel, Singapore, Australia and New Zealand.

According to findings reported by researchers, PJ.2.1 has shown increasing circulation in certain locations. Public Health Ontario surveillance data indicated that the variant accounted for 25.2% of sequenced COVID-19 samples between September 20 and October 17, compared with 16.9% during the preceding four-week period.

These figures represent the proportion of sequenced samples, not the percentage of the entire population infected with the variant.

Why Are Scientists Concerned About Spike Protein Mutations?

One of the major reasons PJ.2.1 is attracting scientific interest is its highly mutated Spike Protein.

The Spike Protein is an important structure on the surface of SARS-CoV-2. It allows the virus to attach to ACE2 receptors present on human cells and subsequently enter them.

According to preliminary laboratory research published in the Journal of Infection in October 2026, PJ.2.1 appears to bind more efficiently to ACE2 receptors than several other variants examined.

This characteristic could provide the virus with an advantage in entering human cells. However, stronger receptor binding alone does not establish that a variant will spread faster between people or cause more serious disease.

Interestingly, the research did not find substantially increased resistance to vaccine-induced antibodies compared with most of the other variants analysed. This is an important distinction because mutations do not automatically mean that existing immunity will become ineffective.

Read more: Can AI Personalise Menopause Care? How Technology Can Transform Women’s Health

What Are the Possible Symptoms of PJ.2.1?

At present, researchers have not established a unique set of symptoms specifically associated with PJ.2.1.

People infected with this lineage may experience symptoms commonly associated with COVID-19 and other respiratory infections, including:

• Fever and chills
• Cough and sore throat
• Runny or blocked nose
• Headache
• Muscle and body aches
• Tiredness and fatigue
• Breathing difficulties in some cases
• Changes in taste or smell

The symptoms can overlap with influenza and other seasonal respiratory illnesses. Therefore, identifying the infection through symptoms alone can be difficult. Medical testing may be required for confirmation.

Does the New Variant Cause More Severe COVID-19?

Despite its international spread and unusual genetic characteristics, there is currently insufficient clinical evidence to establish that PJ.2.1 causes more severe illness, higher hospitalisation rates or increased deaths compared with other circulating COVID-19 variants.

Researchers are continuing to examine its behaviour and potential public health implications.

Older adults, pregnant women, people with weakened immune systems and individuals with certain underlying medical conditions should remain particularly cautious because they may face a higher risk of severe COVID-19.

Precautions People Should Follow

Although the emergence of PJ.2.1 does not automatically indicate another major pandemic wave, basic preventive measures remain important.

People should maintain good hand hygiene, improve indoor ventilation, avoid close contact when experiencing respiratory symptoms and consider wearing masks in crowded indoor spaces, particularly during periods of increased infection.

read more: Crooked Teeth Treatment: Straighten Your Smile with Clear Aligners

Individuals at higher risk should consult healthcare professionals about appropriate vaccination and booster recommendations.

Conclusion

The emergence of PJ.2.1 in Canada and its subsequent detection across the USA, Europe and other regions highlight how SARS-CoV-2 continues to evolve. Its unusual Spike Protein mutations and stronger ACE2 receptor binding have made it an important subject of scientific investigation.

However, there is currently no conclusive evidence that this New COVID Variant causes more severe disease or represents a major public health emergency. Continued genomic surveillance, scientific research and responsible preventive measures will be important in understanding its future impact.

We’re now on WhatsApp. Click to join. 

Like this post?
Register at One World News to never miss out on videos, celeb interviews, and best reads.